Use of lipid vesicles as carriers to introduce actinomycin D into resistant tumor cells

D. Papahadjopoulos, George Poste, W. J. Vail, J. L. Biedler

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Unilamellar lipid vesicles have been used as a carrier vehicle to enhance the uptake of actinomycin D into an actinomycin D resistant Chinese hamster tumor cell line (DC 3F/ADX). The DC 3F/ADX cell line is resistant to actinomycin D as a result of its decreased capacity to transport actinomycin D across the plasma membrane and its able to grow in the presence of concentrations of actinomycin D that are cytotoxic for the sensitive parent cell line (DC 3F). Incubation of resistant DC 3F/ADX cells with actinomycin D containing vesicles produced a 5 fold increase in intracellular drug concentration over that achieved by exposure to identical concentrations of the drug added to the culture medium. Vesicle mediated uptake of actinomycin D into resistant cells produced inhibition of cellular RNA synthesis and cell growth at actinomycin D concentrations that had no inhibitory effect when added as free drug in the culture medium. Dose response measurements established that direct introduction of actinomycin D into resistant cells by means of lipid vesicles resulted in a 200 fold reduction in the concentration of actinomycin D required to inhibit cellular RNA synthesis and a 120 fold reduction in the dose of actinomycin D required to produce a 50% inhibition of cell growth. These results lend strong support to the hypothesis that cellular resistance to actinomycin D is due to a lower capacity to take up actinomycin D as a result of a reduction in the permeability of the cellular plasma membrane to this drug. The potential value of lipid vesicles for introducing other classes of drugs into cultured cells and their possible use in chemotherapy are also discussed.

Original languageEnglish (US)
JournalCancer Research
Volume36
Issue number9
StatePublished - 1976
Externally publishedYes

Fingerprint

Dactinomycin
Lipids
Neoplasms
Pharmaceutical Preparations
Culture Media
Cell Membrane
RNA
Cell Line
Unilamellar Liposomes
Growth
Cricetulus
Tumor Cell Line
Cultured Cells
Permeability

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Use of lipid vesicles as carriers to introduce actinomycin D into resistant tumor cells. / Papahadjopoulos, D.; Poste, George; Vail, W. J.; Biedler, J. L.

In: Cancer Research, Vol. 36, No. 9, 1976.

Research output: Contribution to journalArticle

Papahadjopoulos, D. ; Poste, George ; Vail, W. J. ; Biedler, J. L. / Use of lipid vesicles as carriers to introduce actinomycin D into resistant tumor cells. In: Cancer Research. 1976 ; Vol. 36, No. 9.
@article{e014d9a67922418e988d763dbe610e11,
title = "Use of lipid vesicles as carriers to introduce actinomycin D into resistant tumor cells",
abstract = "Unilamellar lipid vesicles have been used as a carrier vehicle to enhance the uptake of actinomycin D into an actinomycin D resistant Chinese hamster tumor cell line (DC 3F/ADX). The DC 3F/ADX cell line is resistant to actinomycin D as a result of its decreased capacity to transport actinomycin D across the plasma membrane and its able to grow in the presence of concentrations of actinomycin D that are cytotoxic for the sensitive parent cell line (DC 3F). Incubation of resistant DC 3F/ADX cells with actinomycin D containing vesicles produced a 5 fold increase in intracellular drug concentration over that achieved by exposure to identical concentrations of the drug added to the culture medium. Vesicle mediated uptake of actinomycin D into resistant cells produced inhibition of cellular RNA synthesis and cell growth at actinomycin D concentrations that had no inhibitory effect when added as free drug in the culture medium. Dose response measurements established that direct introduction of actinomycin D into resistant cells by means of lipid vesicles resulted in a 200 fold reduction in the concentration of actinomycin D required to inhibit cellular RNA synthesis and a 120 fold reduction in the dose of actinomycin D required to produce a 50{\%} inhibition of cell growth. These results lend strong support to the hypothesis that cellular resistance to actinomycin D is due to a lower capacity to take up actinomycin D as a result of a reduction in the permeability of the cellular plasma membrane to this drug. The potential value of lipid vesicles for introducing other classes of drugs into cultured cells and their possible use in chemotherapy are also discussed.",
author = "D. Papahadjopoulos and George Poste and Vail, {W. J.} and Biedler, {J. L.}",
year = "1976",
language = "English (US)",
volume = "36",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "9",

}

TY - JOUR

T1 - Use of lipid vesicles as carriers to introduce actinomycin D into resistant tumor cells

AU - Papahadjopoulos, D.

AU - Poste, George

AU - Vail, W. J.

AU - Biedler, J. L.

PY - 1976

Y1 - 1976

N2 - Unilamellar lipid vesicles have been used as a carrier vehicle to enhance the uptake of actinomycin D into an actinomycin D resistant Chinese hamster tumor cell line (DC 3F/ADX). The DC 3F/ADX cell line is resistant to actinomycin D as a result of its decreased capacity to transport actinomycin D across the plasma membrane and its able to grow in the presence of concentrations of actinomycin D that are cytotoxic for the sensitive parent cell line (DC 3F). Incubation of resistant DC 3F/ADX cells with actinomycin D containing vesicles produced a 5 fold increase in intracellular drug concentration over that achieved by exposure to identical concentrations of the drug added to the culture medium. Vesicle mediated uptake of actinomycin D into resistant cells produced inhibition of cellular RNA synthesis and cell growth at actinomycin D concentrations that had no inhibitory effect when added as free drug in the culture medium. Dose response measurements established that direct introduction of actinomycin D into resistant cells by means of lipid vesicles resulted in a 200 fold reduction in the concentration of actinomycin D required to inhibit cellular RNA synthesis and a 120 fold reduction in the dose of actinomycin D required to produce a 50% inhibition of cell growth. These results lend strong support to the hypothesis that cellular resistance to actinomycin D is due to a lower capacity to take up actinomycin D as a result of a reduction in the permeability of the cellular plasma membrane to this drug. The potential value of lipid vesicles for introducing other classes of drugs into cultured cells and their possible use in chemotherapy are also discussed.

AB - Unilamellar lipid vesicles have been used as a carrier vehicle to enhance the uptake of actinomycin D into an actinomycin D resistant Chinese hamster tumor cell line (DC 3F/ADX). The DC 3F/ADX cell line is resistant to actinomycin D as a result of its decreased capacity to transport actinomycin D across the plasma membrane and its able to grow in the presence of concentrations of actinomycin D that are cytotoxic for the sensitive parent cell line (DC 3F). Incubation of resistant DC 3F/ADX cells with actinomycin D containing vesicles produced a 5 fold increase in intracellular drug concentration over that achieved by exposure to identical concentrations of the drug added to the culture medium. Vesicle mediated uptake of actinomycin D into resistant cells produced inhibition of cellular RNA synthesis and cell growth at actinomycin D concentrations that had no inhibitory effect when added as free drug in the culture medium. Dose response measurements established that direct introduction of actinomycin D into resistant cells by means of lipid vesicles resulted in a 200 fold reduction in the concentration of actinomycin D required to inhibit cellular RNA synthesis and a 120 fold reduction in the dose of actinomycin D required to produce a 50% inhibition of cell growth. These results lend strong support to the hypothesis that cellular resistance to actinomycin D is due to a lower capacity to take up actinomycin D as a result of a reduction in the permeability of the cellular plasma membrane to this drug. The potential value of lipid vesicles for introducing other classes of drugs into cultured cells and their possible use in chemotherapy are also discussed.

UR - http://www.scopus.com/inward/record.url?scp=0017120922&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017120922&partnerID=8YFLogxK

M3 - Article

VL - 36

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 9

ER -